New Therapeutic Targets for Calcific Aortic Valve Stenosis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Calcific aortic valve stenosis (CAVS) is the most common form of acquired valvular heart disease, present in 3% of the population more than 75 years of age (1). Although risk factors are similar for CAVS and atherosclerosis, ~50% of patients with CAVS do not have clinically significant cardiovascular disease (CVD), suggesting related, but unique, pathophysiology (1). Although surgical aortic valve replacement remains the gold standard treatment for most patients, at least one-third of symptomatic patients with CAVS may not undergo surgical aortic valve replacement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Associations with Valvular Calcification and Aortic Stenosis
Thanassoulis, G., Campbell, C. Y., Owens, D. S., Smith, J. G., Smith, A. V., Peloso, G. M., Kerr, K. F., Pechlivanis, S., Budoff, M. J., Harris, T. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109034 · Cited by 1,008
Rajamannan, N. M., Evans, F. J., Aikawa, E., Grande-Allen, K. J., Demer, L. L., Heistad, D. D., Simmons, C. A., Masters, K. S., Mathieu, P., O'Brien, K. D., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.006767 · Cited by 842
Parhami, F., Morrow, A. D., Balucan, J., Leitinger, N., Watson, A. D., Tintut, Y., Berliner, J. A., & Demer, L. L. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.4.680 · Cited by 619
Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.038 · Cited by 595 · cited 2×
“In this issue of the Journal, 2 reports provide such evidence (16,17).”
BackgroundResultLipoprotein(a): resurrected by genetics
Kronenberg, F., & Utermann, G. (2013) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02592.x · Cited by 521 · cited 1×
“Lp(a) is proatherogenic because of its low-density lipoprotein (LDL) moiety and through additional mechanisms mediated by apo(a) (3,5,6).”
BackgroundPresence of Oxidized Low Density Lipoprotein in Nonrheumatic Stenotic Aortic Valves
Olsson, M., Thyberg, J., & Nilsson, J. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.5.1218 · Cited by 417
Mohty, D., Pibarot, P., Després, J.-P., Côté, C., Arsenault, B., Cartier, A., Cosnay, P., Couture, C., & Mathieu, P. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.154989 · Cited by 181 · cited 1×
“Oxidative stress, calcific nodules, and inflammatory infiltrates play a significant role in CAVS (1), and the accumulation of OxLDL is associated with increased inflammation and may potentiate calcification and matrix remodeling (20,21).”
BackgroundMerki, E., Graham, M., Taleb, A., Leibundgut, G., Yang, X., Miller, E. R., Fu, W., Mullick, A. E., Lee, R., Willeit, P., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.052 · Cited by 124 · cited 1×
“That could be done by several currently available approaches targeting Lp(a), including antisense oligonucleotides specifically directed to apo(a) of Lp(a) currently in phase 1 trials, which lower Lp(a) levels >85% (27), inhibitors of Lp-PLA2 such as darapladib currently being evaluated in phase 3 trials in patients w…”
BackgroundSelf-citation
Cited by
Lindman, B. R., Clavel, M.-A., Mathieu, P., Iung, B., Lancellotti, P., Otto, C. M., & Pibarot, P. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.6 · Cited by 982
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
Capoulade, R., Chan, K. L., Yeang, C., Mathieu, P., Bossé, Y., Dumesnil, J. G., Tam, J. W., Teo, K. K., Mahmut, A., Yang, X., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.020 · Cited by 417
Self-citationBouchareb, R., Mahmut, A., Nsaibia, M. J., Boulanger, M.-C., Dahou, A., Lépine, J.-L., Laflamme, M.-H., Hadji, F., Couture, C., Trahan, S., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.016757 · Cited by 260
Lipoprotein‐associated phospholipase A2: The story continues
Huang, F., Wang, K., & Shen, J. (2020) · Medicinal Research Reviews · doi:10.1002/med.21597 · Cited by 212
“Lp(a) appears to be a causal risk factor for CVD and calcific aortic valve disease (CAVD),221 and Lp‐PLA2 and oxidized phospholipids might be important determinants of the functionality and pathophysiological role of Lp(a).151 Therefore, targeting the Lp(a)‐Lp‐PLA2–OxPL axis might be a viable approach for treating CAV…”
BackgroundYeang (2015) · doi:10.1097/mol.0000000000000171 · Cited by 152
Metadata
- Authors
- Hung, M.-Y., Witztum, J. L., & Tsimikas, S.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 63
- Issue
- 5
- Pages
- 478-480
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W1915791432
- Cited by
- 42
- References
- 8
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.